Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. - Wikidata - wikimedia - TriplyDB

Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease.

Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease.

http://www.wikidata.org/entity/Q37086598

about

Progressive striatal necrosis associated with anti-NMDA receptor antibodies.Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography Marked improvement of anti-N-methyl-D-aspartate receptor encephalitis by large-dose methylprednisolone and plasmapheresis therapy combined with (18)F-fluorodeoxyglucose positron emission tomography imaging: A case report.18F-Fluorodeoxyglucose Positron-Emission Tomography Findings with Anti-N-Methyl-D-Aspartate Receptor Encephalitis that Showed Variable Degrees of Catatonia: Three Cases Report.Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report Bi-insular cortical involvement in anti-NMDA-receptor encephalitis - a case report Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis.Paraneoplastic syndromes and autoimmune encephalitis: Five new things.Autoimmune Encephalitis Sugar for the brain: the role of glucose in physiological and pathological brain function The Laboratory Diagnosis of Autoimmune Encephalitis Autoimmune epilepsies Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management.Diagnostic and therapeutic strategies for management of autoimmune encephalopathies.Decreased occipital lobe metabolism by FDG-PET/CT: An anti-NMDA receptor encephalitis biomarker.Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis.The utility of FDG-PET in complex neurological conditions.New-Onset Headache in Patients With Autoimmune Encephalitis Is Associated With anti-NMDA-Receptor Antibodies.Metabolic topography of autoimmune non-paraneoplastic encephalitis.[Pathophysiology of antibody-associated diseases of the central nervous system].Features and Prognostic Value of Quantitative Electroencephalogram Changes in Critically Ill and Non-critically Ill Anti-NMDAR Encephalitis Patients: A Pilot Study

P2860

Q30540332-BD04E1E9-98EB-4521-8E6E-ECD358CFFECA Q31167257-D045CE50-039E-4175-93C0-655C3F1C605E Q34119652-07CD1F34-A6C9-4F26-A69B-716129015742 Q34965387-64D26A9B-CBC1-4C8F-A5C0-A76C9A4359AB Q35732006-2C762801-2B57-44B3-84B8-4E7852C4686F Q36097936-197C0EDF-A023-449B-AAF5-9E7D6326CECF Q36388180-A7C8539E-22B8-43BF-A1A7-110679CF527D Q36731515-213F6392-8AF8-4C43-8C1F-FF459CB7B3DF Q37011779-36BA13F3-74E0-4522-BFFA-F44CBBB60922 Q37511476-B67400D4-6B99-4330-88B9-13407B3C31AC Q37548955-A81DF027-8417-42C4-822B-9A71C7800E3C Q37717429-777FC11C-7552-43BA-8943-967E359AC069 Q38104380-7645BE13-96F9-4B6D-B0BF-BD1E1F9B53B1 Q38832800-CE0F7ADC-0CB6-455F-BC97-05AD0E01F305 Q45358583-767B8119-2CFA-4370-B02D-EE471F8D0522 Q46178030-34AD8AC7-FDF1-4A54-A7AF-E643CFEB9FF4 Q48148136-8D5D705D-009F-42A9-9A26-1C2FEE1F7A08 Q51729354-AF9856FA-EE66-4079-AF1C-F83805CC3884 Q52744681-F320A0A1-1FCA-4537-AB0C-ACE9323F7D32 Q55461708-42BE72CF-2CC1-439D-B3D6-768DF805E4CA Q57817988-667792D6-C9A3-4962-A2D3-05887F0D1B02

P2860

Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease.

http://www.wikidata.org/entity/Q37086598

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 May 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@en

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@nl

type

label

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@en

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@nl

prefLabel

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@en

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@nl

P1433

Q37086598-D894520B-ED99-4939-A1DC-B8704275B71A

P1476

Q37086598-729B47AA-CA5C-41AC-BDD9-5B48A1D3D56A

P2093

Q37086598-2160916C-FEE2-474B-9587-83FBF2384D36

Q37086598-24CA26F1-88C8-4B42-AA4C-9DFAE0BA1EE8

Q37086598-40B6A3EA-CCBF-4ABB-9BF7-6BF21B5016A6

Q37086598-774DDA15-F35A-4809-8F3D-CD88396D2593

Q37086598-89F31FDA-6ED2-440A-B012-AAD38051EE6E

Q37086598-B24A8153-881B-4A95-B08E-21D62C34038F

Q37086598-DFCEC565-8B14-41D4-BD41-58952454FA78

Q37086598-FB4555E1-AB18-40B9-8329-F31C28FAB64C

P2860

Q37086598-045F3940-C15D-4BF1-A77B-C2873032F3CC

Q37086598-06BDEE2A-B15B-4E13-BC13-F93C5614E538

Q37086598-0CC623D7-F82F-437F-AA28-5AF65371BD25

Q37086598-1F8B23FB-16B5-4B74-B1E9-EE56EE07412D

Q37086598-29C5061E-F50A-465E-9F19-36FC32561476

Q37086598-31F38AD4-1AC6-421F-AF09-2684E82A7E7C

Q37086598-32070994-491A-4C1E-A99D-2F29173F09FE

Q37086598-3396CFB4-86E2-4D5F-8BDE-0D541A48B593

Q37086598-3BD1F9E3-637B-4C2B-A7C4-225247FB59B5

Q37086598-51AA83FF-AF03-4D89-B234-A074779954BE

P304

Q37086598-23BB2B92-C1C6-431D-9474-3D38D99EDBB7

P31

Q37086598-F5918D87-9ACB-4529-8AD4-2961FF25A6E1

P356

Q37086598-D1AD5C0D-E38F-43CC-ABBB-E57B6C12E5C9

P407

Q37086598-DA5D7FB3-401E-43A7-8519-0AF7B982936B

P433

Q37086598-301BC6A0-F66B-403F-A732-8A4C0CF2B774

P478

Q37086598-D6F7FF11-0614-4210-AF65-1E71CACCC101

P50

Q37086598-479649C4-A8AB-479B-BFF9-FD95B1871B38

P577

Q37086598-FB50305C-2598-480E-B030-A7D09E6097A1

P5875

Q37086598-ED6CB0D5-082C-421F-A29F-84A0B94CAEBC

P698

Q37086598-257226DB-2AB6-4DAA-843F-9C8E3C67BD98

P932

Q37086598-D63200D7-5938-427D-A7DE-1669CE229BFD

P356

JNNP-2011-301969

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Fluorodeoxyglucose positron em ...... : distinct pattern of disease.

@en

P2093

Christian Gerloff

http://www.w3.org/2001/XMLSchema#string

Frank Leypoldt

http://www.w3.org/2001/XMLSchema#string

Ingo Kleiter

http://www.w3.org/2001/XMLSchema#string

Jan Lewerenz

http://www.w3.org/2001/XMLSchema#string

Jörg Marienhagen

http://www.w3.org/2001/XMLSchema#string

Mathias Gelderblom

http://www.w3.org/2001/XMLSchema#string

Ralph Buchert

http://www.w3.org/2001/XMLSchema#string

Tim Magnus

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis

Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.

Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis.

Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.

P304

681-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2011-301969

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224918989

http://www.w3.org/2001/XMLSchema#string

P698

22566598

http://www.w3.org/2001/XMLSchema#string

P932

3740122

http://www.w3.org/2001/XMLSchema#string